Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 4,273 articles

Articles by Daniel Marsh

SCHD Sees Inflows Surge During Dip, Data Discrepancy Raises Questions
Markets

SCHD Sees Inflows Surge During Dip, Data Discrepancy Raises Questions

SCHD pulled in up to $5.46B during a price dip, but flow trackers show a wide gap, raising questions about the true scale of dividend fund demand.

SCHD QQQ SPY VIG
AI cloud stocks stumble on Nasdaq-100 debut amid rule change
Markets

AI cloud stocks stumble on Nasdaq-100 debut amid rule change

CoreWeave and Nebius dropped on their Nasdaq-100 debut as a new float-sensitive rule tempered passive demand, triggering a 'sell the news' move after pre-inclusion rallies.

CRWV NBIS QQQ ASTS RKLB TER META
Chip ETF Inflows Surge as AI Trade Broadens Beyond Nvidia
Markets

Chip ETF Inflows Surge as AI Trade Broadens Beyond Nvidia

The VanEck Semiconductor ETF (SMH) attracted $6.93 billion in net inflows on Monday, marking a shift in the AI chip trade as investors moved from leveraged Nvidia bets to broader semiconductor exposure.

SMH NVDA TSM AVGO MU AMD SOXX SOXQ NFLX GOOGL
HIVE Digital Surges on Paraguay AI Validation, But Stock Sale Looms
Markets

HIVE Digital Surges on Paraguay AI Validation, But Stock Sale Looms

HIVE shares surged 20% after Columbia University validated AI training on its Paraguay GPUs, but $214.7 million in stock sale capacity remains, posing dilution risk.

HIVE NVDA
Caterpillar Secures Key Role in Microsoft-Chevron Data Center Power Project
Markets

Caterpillar Secures Key Role in Microsoft-Chevron Data Center Power Project

Caterpillar shares rose 3% after Chevron selected its Solar Turbines unit for a major Microsoft data center power project, solidifying its AI energy play.

CAT CVX MSFT GEV
Final June Social Security Payments Set for June 24; Trust Fund Depletion Looms
Economy

Final June Social Security Payments Set for June 24; Trust Fund Depletion Looms

Social Security's final June payment lands June 24 for those born 21st-31st. Average benefit is $1,934.52, far below the $5,181 maximum. Trust fund depletion looms by 2032.

SPY
Alphabet Stock Tumbles 5.6% on $85B Share Sale and AI Talent Exodus
Markets

Alphabet Stock Tumbles 5.6% on $85B Share Sale and AI Talent Exodus

Alphabet shares dropped 5.6% on a $40B at-the-market stock sale, leadership exits to OpenAI and Anthropic, and soaring AI infrastructure costs, overshadowing strong Q1 revenue and Google Cloud growth.

GOOGL GOOG
AMC Faces Dilution Risk Despite Record Weekend from Toy Story 5
Markets

AMC Faces Dilution Risk Despite Record Weekend from Toy Story 5

AMC shares dipped to $2.79 after Toy Story 5 drove its busiest U.S. weekend of 2026, but recent $150 million share sales and dilution warnings weigh on investors.

AMC
S&P 500 Edges Up, Nasdaq Slips as Micron Surge Offsets Tech Weakness
Markets

S&P 500 Edges Up, Nasdaq Slips as Micron Surge Offsets Tech Weakness

The S&P 500 and Dow edged higher, but the Nasdaq slipped as Micron's nearly 5% gain lifted chip stocks, while rising yields weighed on mega-cap tech.

MU GOOGL MSFT NVDA ABBV APGE CAT V
Dow Rises on Caterpillar, Visa Gains; Nasdaq Slips on Tech Weakness
Markets

Dow Rises on Caterpillar, Visa Gains; Nasdaq Slips on Tech Weakness

The Dow Jones rose 214 points, lifted by Caterpillar and Visa, as U.S.-Iran talks progress eased oil and inflation fears, while the Nasdaq slipped.

CAT V GOOGL SPCE
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Markets

AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash

Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.

APGE ABBV
Definium Shares Surge on LSD-Based Depression Drug Trial Success
Markets

Definium Shares Surge on LSD-Based Depression Drug Trial Success

DFTX shares soared 64.2% premarket after Definium's Phase 3 Emerge trial showed DT120 achieved an 8.1-point placebo-adjusted benefit in major depressive disorder.

DFTX